Mersana Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

December 21, 2016

CAMBRIDGE, Mass., December 21, 2016 -- Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 10, 2017, at 2:30 p.m. PT.

About Mersana Therapeutics                                                          

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms provide for expanded opportunities to provide meaningful clinical benefit to patients.  Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017.  In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.

###

Media Contact

Paul Kidwell
paulkidwell@comcast.net
617-680-1088

Investors Contact

Stern Investor Relations, Inc.
Christina Tartaglia
Christina@sternir.com
(212) 362-1200